Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LPXTI-641 by Lapix Therapeutics for Multiple Sclerosis: Likelihood of Approval
LPXTI-641 is under clinical development by Lapix Therapeutics and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase...
LPXTI-641 by Lapix Therapeutics for Rheumatoid Arthritis: Likelihood of Approval
LPXTI-641 is under clinical development by Lapix Therapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase...
LPXTI-641 by Lapix Therapeutics for Demyelinating Diseases: Likelihood of Approval
LPXTI-641 is under clinical development by Lapix Therapeutics and currently in Phase I for Demyelinating Diseases. According to GlobalData, Phase...
LPXTI-641 by Lapix Therapeutics for Neuromyelitis Optica (Devic's Syndrome): Likelihood of Approval
LPXTI-641 is under clinical development by Lapix Therapeutics and currently in Phase I for Neuromyelitis Optica (Devic's Syndrome). According to...